Skip to main content

New Luminescent Zn(II)-Based Complex with Preventive and Inhibitory Effects on Skin Cancer

Buy Article:

$107.14 + tax (Refund Policy)

The dual ligand of 5-(1-oxoisoindolin-2-yl)isophthalic acid (H2L) and 1,2-bis(4-pyridyl)ethane (bpe) was combined with Zn(II) ions in a DMF-H2O system to produce a Zn(II) compound, i.e., (Zn[L][bpe])n (1). At room temperature, compound 1 is luminescent with luminescent quantum yield of 35.8% and luminescence lifetime of 10.5 ns. For the treatment of skin cancer, its suppression effect against skin cancer was discussed, and the mechanism was investigated. The CCK-8 assay was used to detect the CP’s suppression effect against skin cancer cells. Moreover, real-time RT-PCR was conducted to examine the relative CA19-9 expression in cancer cells.

Keywords: Luminescence; Skin Cancer; Zn(II) Compound

Document Type: Research Article

Affiliations: 1: Pathology Department, Xi’an No. 3 Hospital, Xi’an, Shaanxi, 710000, China 2: Dermatological Department, Ankang Central Hospital, Ankang, Shaanxi, 725000, China

Publication date: 01 May 2022

More about this publication?
  • Science of Advanced Materials (SAM) is an interdisciplinary peer-reviewed journal consolidating research activities in all aspects of advanced materials in the fields of science, engineering and medicine into a single and unique reference source. SAM provides the means for materials scientists, chemists, physicists, biologists, engineers, ceramicists, metallurgists, theoreticians and technocrats to publish original research articles as reviews with author's photo and short biography, full research articles and communications of important new scientific and technological findings, encompassing the fundamental and applied research in all latest aspects of advanced materials.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content